https://orcid.org/0000-0001-6846-8687
References
- Kumar S, Regan F. Management of pregnancies with RhD alloimmunisation. BMJ. 2005;330(7502):1255–1258.
- National Institute for Health and Clinical Evidence. Routine antenatal anti-D prophylaxis for women who are Rhesus D negative. Review of NICE technology appraisal guidance 41; 2008.
- Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 65: The Management of Women with Red Cell Antibodies during Pregnancy; 2014.
- Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, et al. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607–616.
- Mari G, Adrignolo A, Abuhamad AZ, et al. Diagnosis of fetal anemia with doppler ultrasound in the pregnancy complicated by maternal blood group immunization. Ultrasound Obstet Gynecol. 1995;5(6):400–405.
- Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med. 2000;342(1):9–14.
- Dodd JM, Windrim RC, van Kamp IL. Techniques of intrauterine fetal transfusion for women with red-cell isoimmunisation for improving health outcomes. Cochrane Database Syst Rev. 2012;(9):CD007096.
- Zwiers C, van Kamp I, Oepkes D, et al. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn–review on current management and outcome. Expert Rev Hematol. 2017;10(4):337–344.
- Zwiers C, Lindenburg ITM, Klumper FJ, et al. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017;50(2):180–186.
- Liu S, Ajne G, Wikman A, et al. Management and clinical consequences of red blood cell antibodies in pregnancy: a population-based cohort study. Acta Obstet Gynecol Scand. 2021;100(12):2216–2225.
- Birchenall KA, Illanes SE, Lopez F, et al. Neonatal outcomes of pregnancies affected by haemolytic disease of the foetus and newborn and managed with intrauterine transfusion: a service evaluation. Blood Transfus. 2013;11(4):548–552.
- Eder AF. Update on HDFN: New information on long-standing controversies. Immunohematology. 2006;22(4):188–195.
- Li S, He Z, Luo Y, et al. Distribution of maternal red cell antibodies and the risk of severe alloimmune haemolytic disease of the foetus in a Chinese population: a cohort study on prenatal management. BMC Pregnancy Childbirth. 2020;20(1):1–11.
- Spong CY, Porter AE, Queenan JT. Management of isoimmunization in the presence of multiple maternal antibodies. Am J Obstet Gynecol. 2001;185(2):481–484.
- Hadley AG. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transplant Immunol. 2002;10(2–3):191–198.
- Velkova E. Correlation between the amount of anti-D antibodies and IgG subclasses with severity of haemolytic disease of foetus and newborn. Maced J Med Sci. 2015;10(2–3):191–198.
- De Haas M, Thurik FF, Koelewijn JM, et al. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99–113.
- Garner SF, Gorick BD, Lai WYY, et al. Prediction of the severity of haemolytic disease of the newborn: quantitative IgG anti‐D subclass determinations explain the correlation with functional assay results. Vox Sang. 1995;68(3):169–176.
- Scheier M, Hernandez-Andrade E, Fonseca EB, et al. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006;195(6):1550–1556.
- Martinez-Portilla RJ, Lopez-Felix J, Hawkins-Villareal A, et al. Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2019;54(6):722–731.
- Deren Ö, Önderoglu L. The value of middle cerebral artery systolic velocity for initial and subsequent management in fetal anemia. Eur J Obstet Gynecol Reprod Biol. 2002;101(1):26–30.